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coronary heart disease
Anna Meijer, Marij Zuidersma and Peter de Jonge*Abstract
Background: After decades of investigations, explanations for the prospective association between depression and
coronary heart disease (CHD) are still incomplete.
Discussion: Depression is often suggested to be causally related to CHD. Based on the available literature, we
would rather argue that depression can best be regarded as a variable risk marker, that is, a variable that fluctuates
together with mechanisms leading to poor cardiovascular fitness. Despite numerous efforts, no evidence is found
that manipulation of depression alters cardiovascular outcomes - a key premise for determining causality. To explain
the concept of a variable risk marker, we discuss several studies on the heterogeneity of depression suggesting that
depression is particularly harmful for the course of cardiovascular disease when it appears to be a physiological
consequence of the cardiovascular disease itself.
Summary: We conclude that instead of depression being a causal risk factor for CHD, the association between
depression and CHD is likely confounded, at least by the cardiac disease itself.
Keywords: Cardiovascular disease, Depression, Causality, Risk marker, Risk factorBackground
For many decades, researchers and clinicians have
observed an association between depression and coron-
ary heart disease (CHD), and have tried to discover the
mechanisms involved. A fair number of theories have
been formulated and investigated, but no conclusive
explanation exists as to why depression might lead to
CHD and its progression. One potential explanation is
that depression is causally related to the development
and clinical course of CHD, either directly or through
mediating pathways. Suggestive of causality, the associ-
ation between depression and CHD has been consist-
ently found across different settings and patient groups,
as both etiological and prognostic associations between
depression and CHD have been found in various studies
of research groups worldwide [1-4]. However, in the
present review we will argue that, instead of being caus-
ally involved, depression can best be defined as a variable
risk marker of CHD and its progression. We will discuss
this on the basis of Hill’s criteria for causality [5]. In* Correspondence: peter.de.jonge@umcg.nl
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reproduction in any medium, provided the oraddition, we will discuss current evidence in the light of
the idea that symptoms and subtypes of depression that
appear to be a physical consequence of the cardiac
disease are most strongly predictive of adverse cardio-
vascular outcomes.
Principles for establishing causality have been devel-
oped by Bradford Hill [5] (Table 1), which can aid in de-
termining the plausibility of a causal association between
two variables. Below, we will discuss how the principles
most relevant for the association between depression
and CHD (indicated with an *), substantiate the hypoth-
esis that depression is a variable risk marker for CHD.
The principle of strength states that causality is more
likely in stronger associations. The association between
depression and CHD, however, is generally moderate.
Otherwise healthy people with depression have an 80%
higher risk of dying of CHD or having a myocardial
infarction (MI) than those without a depression [2].
Similarly, depressed patients with established CHD have
a two times higher risk of dying of CHD or other causes
[1,2]. Although the association of depression with devel-
opment and progression of CHD is generally moderate,
its magnitude is similar to that of the associations of
other well-known risk factors for CHD, includingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Principles of causality [5]
Principle Explanation
Strength the stronger the association, the more likely is
causality*
Consistency the association exists in different contexts and
times
Specificity the association is specific for the variable and one
particular outcome*
Temporality the variable precedes the outcome*
Dose–response
relationship
an increase in the variable results in an increase in
the outcome*
Plausibility plausible theories/mechanisms for explaining the
association exist*




manipulation of the variable results in changes in
the outcome*
Analogy similar associations exist between different
variables
Principles marked with an * are the principles discussed in the text.
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alcohol consumption and physical activity [6]. The caus-
ality of each of these factors (including depression), as
well as their place in the causal chain towards CHD, re-
mains to be resolved. However, the absence of a strong
association suggests the association is not definitely
causal. Although causality is not excluded as a possibil-
ity, it is also possible that [7,8] other factors, such as
cardiac disease severity and other health-related risk
factors explain at least part of the association between
depression and CHD.
The principle of specificity states that associations are
more likely to be causal when they are specific for one
variable and one outcome. According to Hill the argument
of specificity is difficult to attain, and can only argue
strongly in favor of causality, but can never argue against
it [5]. If an association is very specific (that is, one risk fac-
tor associated with one disease only), then this is strongly
supportive for causality. However, when an association is
not specific, this does not necessarily argue against causal-
ity. For instance, smoking is associated with many disease
outcomes, but may still be causally related to the develop-
ment of some of the diseases. Like smoking, depression is
associated with the outcomes of multiple diseases [9-14],
and etiologically, depression is a risk factor for the devel-
opment and progression of several types of disease [10],
not just CHD. Moreover, other psychological problems
have also been found to be associated with the develop-
ment and progression of CHD, such as anxiety [15,16],
vital exhaustion [17,18], anger and hostility [19]. There-
fore, Hill’s principle of specificity has not been met, mean-
ing that there is no support that depression is definitely a
causal risk factor.The principle of temporality states that, in a causal as-
sociation, the determinant variable must precede the
outcome. This principle means to determine the absence
of causality rather than its presence. That is, an associ-
ation in which the determinant does not precede the
outcome is by definition not causal, but associations in
which the determinant does precede the outcome may
still be confounded. In the association between depres-
sion and CHD, most of the evidence points towards a
bidirectional role of depression in CHD. In one direc-
tion, depression indeed precedes CHD, as depression in
otherwise healthy people is associated with increased
risk for the onset of CHD [2,20-23], with a pooled risk
ratio (RR) of between 1.5 and 2.0 [2,21,22]. In addition,
in patients with existing CHD, depression is associated
with an increased risk of cardiac morbidity and (cardiac)
mortality [1,2,24].
In the other direction, CHD is a potential risk factor
for depression, as CHD is associated with increased
prevalence of depression. An estimated 17% to 27% of
CHD patients have major depressive disorder (MDD),
compared with around 5% in the general population
[25,26]. In addition, CHD in older persons without de-
pression at baseline was found to be associated with an
increased risk of developing depressive symptoms two
years later [27]. Furthermore, a recent study, using the
largest sample (n = 1,117,292) to date, found cardiovas-
cular fitness in healthy young men to predict depression
up to 40 years later, even without cardiac disease being
present [28]. This latter study suggests that poor cardio-
vascular fitness causes depression later in life, but may
also mean that both depression and CHD are caused by
other factors, such as family environment and inactivity.
Thus, the principle of temporality has been met as de-
pression precedes CHD. However, this does not mean
that the relation is definitely causal. Instead, the pres-
ence of the relationship in the opposite direction (that
is, CHD precedes depression) rather suggests against
causality.
The principle of a dose–response relationship states
that an association is more likely to be causal when
there is a dose–response relationship between the vari-
able and the outcome. There is evidence for such a rela-
tionship between self-reported depressive symptoms and
cardiovascular outcomes: that is, the more severe the
(symptoms of) depression, the stronger the association
with CHD [29,30]. However, studies comparing the
prognostic value of self-reported symptoms of depres-
sion with the prognostic value of a diagnosis of MDD
report mixed results. Two studies [31,32] found a diag-
nosis of MDD to be more strongly predictive of cardio-
vascular outcomes in CHD patients. In contrast, two
other studies [33,34] found self-reported symptoms of
depression to be a stronger predictor of cardiovascular
Meijer et al. BMC Medicine 2013, 11:130 Page 3 of 8
http://www.biomedcentral.com/1741-7015/11/130outcomes in CHD patients. In addition, we recently
found that self-reported symptoms of depression were a
stronger predictor of poor cardiovascular outcomes than
a diagnosis of MDD in a sample of 2,493 MI patients
[30]. Finally, in our recent study of 767 MI patients, it
was found that an increase of symptoms of depression
immediately after an MI predicted cardiac events,
whether or not these symptoms reached the level of se-
verity of a clinical depression [35].
Thus, there is evidence for a dose–response relation-
ship between self-reported depressive symptoms and
cardiovascular outcomes, which is supportive of the idea
of causality. However, a diagnosis of MDD is not neces-
sarily a stronger predictor of cardiovascular outcomes
than self-reported depressive symptoms, which seems
contradictive. In research, self-report questionnaires are
used more often than clinical diagnoses of depression. A
characteristic of a Diagnostic Statistical Manual of Mental
Disorders (DSM)-IV diagnosis of depression is that by def-
inition, the symptoms of depression cannot be the result
of a physical disease or medication use [36]. In contrast,
self-report questionnaires do not distinguish between dif-
ferent causes of symptoms of depression. Therefore, it
cannot be excluded that depressive symptoms reported on
self-reported questionnaires may be an expression of
CHD symptoms, which could explain the association with
worse cardiovascular prognosis.
The principle of plausibility states that causality is
more likely when there are plausible theories or mecha-
nisms to explain an association. Indeed, several plausible
(mediating) mechanisms have been proposed through
which depression can cause poor CHD outcomes. These
mechanisms include, among others, elevated inflamma-
tion or platelet activation, changes in autonomic nervous
system functioning and in hypothalamic-pituitary-ad-
renal axis functioning [20,37]. They may be causally in-
volved in the association between depression and CHD.
On the other hand, instead of forming pathways between
depression and CHD, they may also confound the asso-
ciation by underlying the development of both depres-
sion and CHD. Biological causes for depression are
thought to involve vascular disease, atherosclerosis and
systemic inflammation [38], which are processes also
strongly involved in cardiac disease. For example, there
is evidence that systemic inflammation is involved in the
development of both depression and CHD [39-43].
The principle of experimental manipulation states that
an association is more likely to be causal when manipu-
lation of the determinant variable results in changes in
the outcome. This may be the most important principle
arguing against causality in the association between de-
pression and CHD. Studies using depression treatment
methods recommended by clinical guidelines, in which
attempts have been made to improve depression(CREATE [44], SADHART [45,47], ENRICHD [46]) have
been moderately effective in doing so, but did not result
in subsequent improvement of CHD outcomes. Poten-
tially, the improvements in depression were too small to
affect CHD outcomes. On the other hand, it may indi-
cate that depression is not causal of CHD.
In summary, despite decades of research, based on the
evidence for criteria of causality discussed above, evi-
dence appears to be against depression as a causal risk
factor for CHD. Depression can, therefore, best be con-
ceptualized as a variable risk marker for CHD and its
progression [48].
The consequences of this conceptualization of the as-
sociation between depression and cardiovascular disease
are, most importantly, that variations in depression are
associated with variations in CHD and cardiovascular
outcomes, but that experimental manipulation of de-
pression does not change the CHD outcomes, as shown.
Although depression is considered a mental disorder, for
some CHD patients, some depressive symptoms may
occur as a physical response to the cardiac disease. For
example, fatigue is a symptom of depression, but may
also be a consequence of CHD. Therefore, we propose
an alternative theory, based on the fact that depression
is highly heterogeneous, and typically, those symptoms
and subtypes of depression that are most strongly asso-
ciated with cardiac prognosis are those that are most
likely a physical response to cardiac disease. The follow-
ing areas of research will be discussed in light of the the-
ory of cardiac disease severity as a confounder in the
association between depression and CHD: 1) the
cardiotoxicity of somatic/affective depressive symptoms;
2) the cardiotoxicity of treatment-resistant depression;
and 3) residual confounding.
Discussion: depression as a marker of cardiac
disease severity
Somatic/affective vs. cognitive/affective symptoms
There is evidence for two prototypical symptom clusters
of depression in CHD patients, consisting of somatic/
affective and cognitive/affective symptoms. Somatic/
affective symptoms of depression are physical symptoms,
such as fatigue, psychomotor changes, changes in appe-
tite and weight, difficulty working, sleeping problems
and pain [38]. Cognitive/affective symptoms include
symptoms such as depressed mood, loss of interest, sui-
cidal ideation, pessimism, interpersonal sensitivity and
feelings of failure, guilt, self-dislike, self-accusation and
self-criticism [38]. Due to their somatic nature, somatic/
affective symptoms may conceptually show greater over-
lap with cardiac disease than cognitive/affective depres-
sive symptoms. That is, somatic/affective symptoms may
be a direct (fatigue) or indirect (work difficulties) phys-
ical consequence of the cardiac disease. If cardiac disease
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depression and cardiac prognosis, then particularly som-
atic/affective depressive symptoms should be related to
worse cardiac prognosis and to pathophysiological
underlying processes.
Somatic/affective symptoms indeed are more strongly
associated with worsened cardiac outcomes than cogni-
tive/affective symptoms [38]. In a study of patients with
stable CHD, each somatic symptom of depression was
associated with a 14% higher risk of new cardiac events
after adjustment for cardiac risk factors, whereas cogni-
tive symptoms of depression were not [49]. In another
study, somatic/affective and appetitive symptoms of de-
pression were both associated with, respectively, 35%
and 42% increased risk of cardiac mortality and morbid-
ity, but cognitive/affective symptoms were not [50]. In
MI patients, somatic/affective symptoms were found to
be more strongly associated with cardiac health status
(left ventricular ejection fraction (LVEF), Killip class and
previous MI) and cardiac prognosis and mortality than
cognitive/affective symptoms in several studies [51-53].
Smolderen et al. found that somatic symptoms of de-
pression were associated with long-term outcomes in MI
patients, but cognitive symptoms of depression were not
[54]. Recently, Bekke-Hansen et al. found that somatic/
affective symptoms at 12 months after an MI predicted
all-cause and cardiac mortality, but no such association
was found for cognitive/affective symptoms [55]. In con-
trast, two studies found cognitive/affective depressive
symptoms to be more predictive of cardiac outcomes
[56,57]. However, these two studies were both performed
in coronary artery bypass patients evaluating depressive
symptoms postoperatively, whereas all former studies
evaluated depressive symptoms in CHD patients (either
stable CHD or within several months after an acute car-
diac event). One other study in MI patients found three
out of four somatic symptoms of depression (fatigue,
appetite problems and psychomotor changes), but also
two out of five cognitive depressive symptoms (lack of
interest and suicidal ideation) to be associated with poor
cardiac outcomes [58]. However, this latter study was
the only study that assessed depressive symptoms with a
diagnostic interview. Thus, in all studies on CHD pa-
tients, except those just after coronary artery bypass
grafting (CABG) surgery, self-reported somatic/affective
symptoms of depression predicted poor cardiac out-
comes more than cognitive/affective symptoms. This is
suggestive of a specific link between self-reported som-
atic/affective symptoms and CHD.
Somatic/affective symptoms may be associated more
with different underlying mechanisms than cognitive/
affective symptoms, resulting in somatic affective symp-
toms being particularly cardiotoxic [59]. Most studies
only find a link between physiological processes andsomatic/affective symptoms. One study found that low
heart rate variability, which is associated with worsened
cardiac outcomes, was associated with somatic/affective
symptoms but not with cognitive/affective symptoms of
depression in patients with stable CHD [60]. Also, in
several studies, somatic/affective symptoms, but not cog-
nitive/affective symptoms, have been associated with
atherosclerosis in otherwise healthy people [61,62], and
with visceral obesity [63]. In addition, otherwise healthy
patients with atypical depression (increased appetite, in-
creased sleep) were found to have higher body mass
index and higher risk of metabolic syndrome than pa-
tients with melancholic depression [64]. Apparently,
somatic/affective, but not cognitive symptoms of depres-
sion are associated with biological mechanisms involved
in CHD. This link may, therefore, be particularly strong
in patients with a recent cardiac event, such as a myo-
cardial infarction. Delisle et al., for example, found that
hospitalized depressed MI patients had higher Beck
Depression Inventory somatic symptom scores than did
depressed psychiatry outpatients [65]. Together, findings
on the relationship of somatic/affective symptoms with
cardiac prognosis and underlying biological mechanisms
suggest that somatic/affective depressive symptoms are a
physiological consequence of CHD, which explains at
least part of the association between the two.
Cognitive/affective and somatic/affective symptoms
often occur together. These two symptom clusters of de-
pression are in fact continuous phenomena, making it
difficult to give an exact figure of the prevalence of the
two subtypes and their co-occurrence. We believe that
there will be continuous transitions between two proto-
typical forms of depression, while any mixture of cogni-
tive and somatic affective symptoms may develop in a
particular individual with CHD [38]. Both clusters may
thus be present at the same time, in some cases there
may be a sequential pattern of symptoms, and in some a
clear predominance of one of the clusters may be
present. Future research should further explore these is-
sues in CHD patients. Thus, although both symptom
profiles may be present within the same individual, the
somatic/affective symptom profile is often found to be
associated with worse cardiovascular prognosis, inde-
pendent of the cognitive/affective symptom profile.
Treatment-resistant depression and cardiac prognosis
Another subtype of depression that is related to cardiac
disease is treatment-resistant depression, which is par-
ticularly associated with the risk of poor cardiovascular
outcomes [38,66]. In the Montreal Heart Attack Re-
adjustment Trial (M-Hart), the effects of a psychosocial
nursing intervention on psychological distress, mortality
and new cardiovascular events were evaluated in 1,376
post-MI patients [67]. Patients who showed persisting or
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had an increased risk of dying or of cardiac hospital
readmissions within the subsequent year [68]. Milani et al.
evaluated the effects of a cardiac rehabilitation program
with exercise training on depressive symptoms and all-
cause mortality in CHD patients. They found patients with
persisting or increasing depressive symptoms during the
rehabilitation program had higher all-cause mortality rates
than patients with decreasing or constantly low levels of
depressive symptoms [69]. More recently, this finding was
replicated in CHD patients with additional heart failure
[70]. The Myocardial Infarction and Depression Interven-
tion Trial (MIND-IT) evaluated the effects of the antide-
pressants mirtazapine and citalopram on depression and
risk of new cardiac events in depressed MI patients. Pa-
tients who did not respond to the treatment significantly
more often had a new cardiac event (25.6% vs. 7.4%) com-
pared with those who did respond [71]. The Sertraline
Antidepressant Heart Attack Trial (SADHART) included
depressed acute coronary syndrome patients in a six-
month randomized treatment trial of sertraline vs. pla-
cebo. Patients with treatment-resistant depression were at
increased risk of all-cause mortality up until eight years
after treatment initiation, and this increased risk was also
found for patients with persisting depression who were
treated with placebo [45,47]. Similar results were found in
the Enhancing Recovery in Coronary Heart Disease
(ENRICHD) trial, which evaluated the effects of six
months’ treatment with cognitive behavioral therapy
supplemented with sertraline on cardiovascular outcomes
and mortality in depressed MI-patients. Patients in whom
the depressive symptoms did not improve had increased
mortality rates compared to those whose depressive symp-
toms did improve [72,73]. Recently, the investigators
showed that this increased risk was due to the persistence
of somatic/affective depressive symptoms, but not to cog-
nitive/affective depressive symptoms [73].
One explanation for the association between treatment-
resistant depression and worse cardiac prognosis is that
underlying factors relate to both the treatment
nonresponse and the poor cardiac prognosis, such as the
cardiac disease itself. That is, patients with treatment-
resistant depression may have a constantly severe or even
deteriorating underlying cardiac disease. A constantly
severe or deteriorating heart disease would be reflected in
depressive symptoms that persist over time, do not
respond to traditional depression treatment, and that are
associated with worse cardiovascular prognosis. This is
consistent with the hypothesis that depression is a variable
risk marker for cardiac outcomes.
Residual confounding
If depression were a variable risk marker, one would
expect the association between depression and cardiacprognosis to be attenuated after adjustment for potential
confounders, like the severity of the cardiac disease. Still,
the association between depressive symptoms and car-
diovascular prognosis remains, even after adjustment for
severity of the heart disease and other potential con-
founders [1,2]. This suggests that depression is an inde-
pendent risk factor for CHD. Instead of this, we would
rather argue that this is the result of incomplete adjust-
ment. When cardiac disease severity is incompletely or
imprecisely measured, statistical adjustment for cardiac
disease severity may lead to an underestimation of its
underlying role. This phenomenon is known as residual
confounding [74] (that is, due to imprecise measurement
of parameters) or unmeasured confounding (that is, due
to unmeasured parameters). A simulation study showed
that associations found in observational studies, such as
those between depression and cardiac prognosis, can be
generated by residual and unmeasured confounding alone
[75]. In contrast to observational studies, experimental
studies with randomized designs minimize confounding
by unmeasured as well as measured factors. If an associ-
ation is found in an observational study, but not in an
experimental study, it is likely that unmeasured or impre-
cisely measured factors confound the association. This
may be the case for depression and cardiac prognosis, as
observational studies consistently find an association be-
tween depression and cardiac prognosis [1-3], but experi-
mental manipulation of the depression in a randomized
trial does not affect cardiac prognosis [45-47,76].Conclusion
We suggest that, based on current evidence, depression
can best be defined as a non-causal variable risk marker
for CHD, and causality cannot be established. In addition,
recent literature on the heterogeneity of depression dem-
onstrates that subtypes of depression that are specifically
cardiotoxic may be present in some patients. Although we
believe that particularly the role of underlying cardiovas-
cular disease processes in explaining the association
between (subtypes of) depression and CHD is currently
underrated, there are likely additional mechanisms under-
lying the association. As the association between depression
and CHD is complex, and depression is strongly heteroge-
neous in CHD patients, different mechanisms and combi-
nations of mechanisms are probably involved in different
patients.
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